These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. Lopez Hänninen E; Kirchner H; Atzpodien J J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829 [TBL] [Abstract][Full Text] [Related]
8. [Phase II trial of treatment of metastatic renal adenocarcinoma with recombinant leukocyte interferon (rDNA IFN-alpha 2)]. Dorval T; Palangie T; Garcia-Giralt E; Jouve M; Bretaudeau B; Falcoff F; Coninx P; Schwab D; Pouillart P Bull Cancer; 1985; 72(5):470-1. PubMed ID: 4074917 [No Abstract] [Full Text] [Related]
9. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma. Figlin RA; Pierce WC; Belldegrun A Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686 [No Abstract] [Full Text] [Related]
10. Use of biological response modifiers for management of renal cell carcinoma. Wilkinson M; Aronson F Urol Int; 1991; 46(3):304-8. PubMed ID: 1926644 [TBL] [Abstract][Full Text] [Related]
11. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma. Little B; Young M; Ho KJ Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831 [TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial]. Jacqmin D; Bergerat JP; Dufour P; Bollack C; Prévot G; Jurascheck F; Bailly G; Degaris S; Oberling F J Urol (Paris); 1987; 93(8):463-6. PubMed ID: 3440838 [TBL] [Abstract][Full Text] [Related]
13. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions? Young RC N Engl J Med; 1998 Apr; 338(18):1305-6. PubMed ID: 9562587 [No Abstract] [Full Text] [Related]
14. Interferon alpha for the treatment of advanced renal cancer. Ravaud A; Dilhuydy MS Expert Opin Biol Ther; 2005 Jun; 5(6):749-62. PubMed ID: 15952906 [TBL] [Abstract][Full Text] [Related]
15. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. Negrier S; Escudier B; Lasset C; Douillard JY; Savary J; Chevreau C; Ravaud A; Mercatello A; Peny J; Mousseau M; Philip T; Tursz T N Engl J Med; 1998 Apr; 338(18):1272-8. PubMed ID: 9562581 [TBL] [Abstract][Full Text] [Related]
16. Renal cell cancer: is there long-term survival advantage from cytokine treatment? Oliver RT Eur J Cancer; 1994; 30A(9):1214-6. PubMed ID: 7999400 [No Abstract] [Full Text] [Related]
17. Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study. Atzpodien J; Kirchner H; de Mulder P; Bodenstein H; Oliver T; Palmer PA; Franks CR; Poliwoda H Cancer Biother; 1993; 8(4):289-300. PubMed ID: 7804370 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of renal cell carcinoma. Haas GP; Hillman GG; Redman BG; Pontes JE CA Cancer J Clin; 1993; 43(3):177-87. PubMed ID: 8490757 [TBL] [Abstract][Full Text] [Related]
19. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611 [TBL] [Abstract][Full Text] [Related]